Background: Metformin has been shown to inhibit the proliferation and migration of vascular wall cells. However, the mechanism through which metformin acts on atherosclerosis (AS) via the long non-coding RNA taurine up-regulated gene 1 (lncRNA TUG1) is still unknown. Thus, this research investigated the effect of metformin and lncRNA TUG1 on AS. Methods: First, qRT-PCR was used to detect the expression of lncRNA TUG1 in patients with coronary heart disease (CHD). Then, the correlation between metformin and TUG1 expression in vitro and their effects on proliferation, migration, and autophagy in vascular wall cells were examined. Furthermore, in vivo experiments were performed to verify the anti-AS effect of metformin and TUG1 to provide a new strategy for the prevention and treatment of AS. Results: qRT-PCR results suggested that lncRNA TUG1 expression was robustly upregulated in patients with CHD. In vitro experiments indicated that after metformin administration, the expression of lncRNA TUG1 decreased in a time-dependent manner. Metformin and TUG1 knockdown via small interfering RNA both inhibited proliferation and migration while promoted autophagy via the AMPK/mTOR pathway in vascular wall cells. In vivo experiments with a rat AS model further demonstrated that metformin and sh-TUG1 could inhibit the progression of AS. Conclusion: Taken together, our data demonstrate that metformin might function to prevent AS by activating the AMPK/mTOR pathway via lncRNA TUG1.
Introduction
Atherosclerosis (AS) is a chronic disease that can be caused by multiple factors. Autophagy has become a new research interest with the increased understanding of the pathogenesis of AS. Studies have shown that autophagy is closely related to cancer, neurodegenerative diseases, and cardiovascular diseases. [1] [2] [3] The activation of autophagy in vascular wall cells can protect endothelial cells and smooth muscle cells from damage caused by risk factors and contribute to the stability of plaques, whereas the inhibition of autophagy can accelerate apoptosis, necrosis, and aging, thus making plaques more vulnerable.
metabolic disease, myocardial infarction, and AS. For example, the lncRNA NEXN-AS1 has been shown to mitigate AS by regulating activity of the actin-binding protein NEXN. 9 The lncRNA taurine up-regulated gene 1 (TUG1)
is located on chromosome 22q12.2 and has a length of 7.1 kb; it was originally identified in taurine-treated mouse retinal cells. 10 Increasing evidence indicates that the dysregulation of TUG1 is involved in the development of a variety of diseases including cancer, ischemic stroke, and diabetes. [11] [12] [13] [14] However, there is limited knowledge on the function of TUG1 at the molecular level, as well as its exact role in AS. AMP kinase (AMPK) is a key energy sensor that recognizes ATP in cells; it is activated by hepatic protein kinase B1 under conditions of starvation or energy consumption and is a negative regulator of mammalian target of rapamycin (mTOR). The inhibition of mTOR phosphorylation mediated by AMPK phosphorylation can induce autophagy in many different cell types. 15, 16 Metformin is a widely used antidiabetic drug used to treat patients with type 2 diabetes mellitus. Studies have shown that it can exert protective effects against cardiovascular diseases; specifically, metformin can activate autophagy and provide cardioprotective effects in δ-sarcoglycan-deficient hearts. 17 Further, metformin represses cardiac apoptosis through inhibition of the Forkhead box O1 (FoxO1) pathway. 18 In addition, clinical trials have shown that metformin has anti-AS properties, [19] [20] [21] providing data for its potential use for the primary prevention of AS. However, the exact mechanism through which metformin inhibits AS via TUG1, and the mechanism associated with the TUG1-modulated activation of autophagy is currently unknown. Accordingly, the present study aimed to observe the correlation between metformin and TUG1 expression in vitro, as well as their effects on proliferation, migration, and autophagy in vascular wall cells. Then, in vivo experiments were performed to verify the anti-AS effect of metformin and TUG1 to provide a new strategy for the prevention and treatment of AS.
Materials and Methods

Cell Culture
Human umbilical vein endothelial cells (HUVECs) were purchased from the Xiangya Cell Bank of Central South University (Changsha, China). Cells were cultivated in RPMI1640 medium (Hyclone, UT, USA) supplemented with 10% fetal bovine serum (Biological Industries, Beit-Haemek, Israel) and 1% penicillin/streptomycin (Solarbio, Beijing, China) at 37°C in an atmosphere containing 5% CO 2 .
Plasmid Construction and Transfection
TUG1 small interfering RNA (si-TUG1 #1, #2), siRNA negative control (si-NC), adeno-associated virus carrying TUG1 shRNA (sh-TUG1), and empty vector (sh-NC) were purchased from GenePharma (Shanghai, China). CRISPR/cas9 single guide RNA with TUG1 overexpression (sg-TUG1 #1, #2, #3) and the corresponding control (sg-NC) were purchased from Syngentech (Beijing, China). The sequences of siRNA/ shRNA/sgRNA are listed in Table S1 . Transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. 
Clinical Blood Samples
5-Ethynyl-2′-Deoxyuridine Assay
Cells were seeded in 96-well culture plates (3 × 10 3 cells/ well) and exposed to media with metformin or transfected Quantitative Real-Time Reverse Transcriptase PCR
RNA from peripheral blood according to the instructions of the kit (Bioteke, Beijing, China). Total RNA from cells/tissues was isolated with TRIzol reagent (Invitrogen), For quantitative reverse transcriptase PCR (qRT-PCR), 1000 ng total RNA was reverse-transcribed into first-strand cDNA using a PrimeScript RT Reagent Kit (Takara Bio, Shiga, Japan). RNA expression was examined by qRT-PCR using a Two
Step SYBR PrimeScript RT-PCR Kit (Takara) with the Illumina P05775 system (Illumina, San Diego, CA, USA). The primer sequences used are listed as follows: lncRNA TUG1 (human): forward 5′-CCACTTTGTCACAAGAGA AGGC-3′, reverse 5′-CACAAATTCCCATCATTCCC-3′; lncRNA TUG1 (rat): forward 5′-TGCTGAAGTTGTT TGCCTGC-3′, reverse 5′-TCCTTGGTGGAATTGGGCAC -3′; GAPDH (human): forward 5′-TCACCATCTTCCCA GGAGCGAG-3′, reverse 5′-TGTCGCTGTTGAAGTCAG AG-3′; GAPDH (rat): forward 5′-GGTGAAGGTCGGTG TGAACG-3′ and reverse 5′-CCACTTTGTCACAAGAGA AGGC-3′. Relative gene expression was calculated using the 2 −ΔΔCt method with GAPDH used as a normalization control. 22 
Western Blotting
Cells were lysed with RIPA buffer (Solarbio) supplemented with a complete protease inhibitor cocktail (KangChen, Shanghai, China) for 30 min on ice. Then, the cell debris was collected and centrifuged at 12,000 g for 15 min. The protein concentration was detected using the bicinchoninic acid (BCA) Protein assay kit (Beyotime, Beijing, China). Equal concentrations of protein extracts were separated by 8-12% SDS-PAGE and transferred to PVDF membranes. The membranes were then blocked with 5% nonfat milk for 2 h and incubated with primary antibodies against LC3II, P62, AMPK, mTOR, and ATG3 (1:1000, Abcam, Cambridge, UK), p-AMPK (Thr172) and p-mTOR (Ser2448) (1:1000, Cell Signal Technology, Danvers, MA, USA), and GAPDH (1:1000, Goodhere, Inc., Hangzhou, China) at 4°C overnight. Subsequently, the membranes were incubated with HRPconjugated secondary antibodies (1:5000; Cell Signaling Technology, Danvers, MA, USA) for 1.5 h at room temperature. An enhanced chemiluminescence kit (Millipore, Billerica, MA, USA) was used to visualize the blots, and protein bands were quantified using ImageJ software.
Laboratory Animals and Grouping
A total of 70 male Wistar rats weighing 170 ± 10 g were purchased from Changsha Tianqin Biotechnology Co., Ltd (License number: SCXK (Xiang) 2014-0011, Changsha, China). All animal experiments were approved by the Experimental Animal Ethics Committee of Guizhou Provincial People's Hospital. The rats were randomly divided into seven groups with 10 rats in each group as follows: control group (no AS), AS model group, sh-NC group, sh-TUG1 group, metformin group, metformin + sh-TUG1 group, and atorvastatin positive control group. Rats in the control group were fed a normal diet, whereas all other rats were fed a high-fat diet and vitamin D 3 to induce AS (the composition of the rat diet is listed in Table  S1 ) and was in accordance with the literature. 23, 24, 25 Food was provided adlibitum. After allowing the rats to acclimatize for 30 days, 40 μL sh-TUG1 (1.1 × 10 13 vector genomes/mL) or empty vector was injected through the sublingual vein of rats in the corresponding group. Furthermore, in the metformin group, rats were given 100 mg/kg/day metformin (BristolMyers Squibb, New York, USA) via intragastrical administration for 30 days. Rats in the atorvastatin positive control group were given 2.1 mg/kg/day atorvastatin (Jialin Pharmaceutical, Beijing, China) via intragastrical administration for 30 days. Except those of the control group, the other rats were maintained on a high-fat diet, and all rats were then sacrificed for further data analysis. All animal studies were approved by the Ethics Committee of Guizhou Provincial of People's Hospital, and conformed to the Guide for Care and Use of Laboratory Animals by the National Institutes of Health (NIH).
Hematoxylin and Eosin Staining
To observe the changes in the aortic root tissue morphology, hematoxylin and eosin staining (H&E) was performed as follows. Tissues fixed in 4% paraformaldehyde were placed in decreasing concentrations of alcohol, cleared with xylene, dipped in wax, embedded in wax blocks, and sliced into 5-μm sections. Briefly, the sections were dewaxed, stained with hematoxylin followed by 1% hydrochloric acid alcohol, stained with eosin solution, dehydrated with a gradient alcohol series, and cleared with xylene. The slides were then observed using a microscope (40×, Olympus) to identify pathological changes.
Immunohistochemistry
Paraffin-embedded artery tissue sections were deparaffinized in xylene and rehydrated through a graded series of ethanol solutions (100-70%). Sections were heated in EDTA (Zsgbbio, Beijing, China) for 15 min and incubated for 10 min in 3% H 2 O 2 . Thereafter, sections were blocked with 10% goat serum (Bioss, Beijing, China) for 30 min at 37°C. The slides were then incubated separately with primary antibodies against LC3 or p62 (1:100, Proteintech, Wuhan, China) at 4°C overnight. The next day, the IgG-HRP conjugated secondary antibody (Bioss) was added and samples were incubated for 1 h at room temperature, followed by the addition of 3, 3′-diaminobenzidine (DAB, Zsgb-bio) and hematoxylin counterstain. Tissues were then microscopically observed and photographed (200×, Olympus). DAB staining was analyzed by two pathologists as previously described. 26 
Statistical Analysis
Data were calculated as the mean from at least three independent experiments. Numerical data are presented as the mean ± SD. All statistical analyses were performed using GraphPad 7.0 software (GraphPad Software, Inc., La 
Results
Expression Levels of TUG1 in Patients with CHD and in Cells Incubated with Metformin
To investigate the correlation between lncRNA TUG1 and AS, qRT-PCR was used to detect TUG1 expression in the peripheral blood of healthy controls and patients with CHD. The results suggested that TUG1 expression was robustly upregulated in patients with CHD, compared with that in healthy controls ( Figure 1A) . Then, cells were incubated with metformin (10 mmol/L) for 24, 48, or 72 h. As shown in Figure 1B , the expression of TUG1 was downregulated in a time-dependent manner.
Metformin Suppresses Proliferation and Migration while Induces Autophagy in HUVECs
First, HUVECs were incubated with metformin at different concentrations (0, 2, 5, 10, 15, or 20 mmol/L) for 24, 48, or 72 h. The CCK-8 assay results indicated that metformin had a concentration-and time-dependent inhibitory effect on cell growth in HUVECs (Figure 2A) . A concentration of 10 mmol/L metformin effectively inhibited cell proliferation without causing changes in cell morphology; thus, 10 mmol/L was the drug concentration used for subsequent experiments. Furthermore, the EdU assay showed that cells incubated with metformin for 48 h showed significantly supressed proliferation ability compared with that of the control group ( Figure 2B ). Then, we performed a wound healing assay, the results showed that metformin could reduce HUVEC migration in a time-dependent manner ( Figure 2C ). To validate the autophagy-inducing effects of metformin on HUVECs, we transfected the cells with mRFP-GFP-LC3 lentivirus to observe LC3 dots. As shown in Figure 2D , the numbers of both yellow and red dots were markedly increased in metformin-treated HUVECs compared with those in the control group. Lastly, the cells were treated with metformin at different time points (0, 3, 6, 12, 24, 36 h), we found that it could downregulate the expression of p62 and increase the ratio of LC3II/LC3I ( Figure 2E ). Moreover, the changes in p62 expression and the LC3II/LC3I ratio were most prominent at 24 h; thus, we chose 24 h as the incubation time for subsequent Western blotting experiments.
si-TUG1 Suppresses Proliferation and Migration while Induces Autophagy in HUVECs
Next, HUVECs were transfected with si-TUG1(#1, #2) to knock down the expression of TUG1. Following transfection, TUG1 expression decreased sharply in the si-TUG1 groups compared with that in the si-NC group ( Figure 3A) . Similar to the results of metformin treatment, we found that knockdown of TUG1 expression by siRNA inhibited proliferation ( Figure 3B , C and F) and migration ( Figure 3D and G), while promoted autophagy ( Figure 3E , H and I) in HUVECs.
Metformin Activates the AMPK/mTOR Pathway in HUVECs via lncRNA TUG1
First, the transfection efficiency of TUG1 overexpression (OE #1, #2, #3) was measured by qRT-PCR ( Figure 4A ). OE #1 resulted in the greatest overexpression efficiency and was thus selected for subsequent experiments. Second, we found that metformin could increase the expression of p-AMPK/AMPK, ATG3, and LC3II/LC3I and decrease the expression of p-mTOR/mTOR and p62 ( Figure 4B-G) . In addition, the effects of metformin on the AMPK/mTOR pathway were partially reversed by OE #1 transfection.
Third, CCK-8 and wound healing assays were conducted ( Figure 4H and I); here, OE #1 obviously reversed the metformin-induced effects on proliferation and migration.
si-TUG1 Induces Autophagy in HUVECs via the AMPK/mTOR Pathway
Western blotting was then used to detect the protein levels of AMPK, p-AMPK, mTOR, p-mTOR, ATG3, p62, and LC3 after cells were transfected with si-TUG1 (#2, 50 nm). si-TUG1 (#2) resulted in better knockdown efficiency and was thus selected for subsequent experiments. As expected, the expression of p-AMPK/AMPK, ATG3, and LC3II/LC3I was upregulated, whereas that of p-mTOR/mTOR and p62 was downregulated by si-TUG1 ( Figure 5A-F) . However, the effect of si-TUG1 on the AMPK/mTOR pathway was reversed by treatment with Compound C (C.C, 50 μmol/L, an AMPK inhibitor), which suggested that TUG1 knockdown could activate the AMPK/mTOR pathway in HUVECs. In addition, as shown in Figure 5G and H, C.C reversed the effects on proliferation and migration induced by si-TUG1. Figure 5I shows the technical rote of metformin and lncRNA TUG1 in AS.
Anti-AS Effects of Metformin and lncRNA TUG1 in vivo
Finally, we assessed the effects of metformin and lncRNA TUG1 in the AS rat model. Histopathological changes were observed through H&E staining, and aortic root lesion sizes were significantly decreased in the metformin and sh-TUG1 groups compared with those in the AS model or empty vector group, demonstrating that metformin and sh-TUG1 have protective effects on high-fat diet-induced AS injury ( Figure 6A A B
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Relative and C). Immunohistochemistry was then used to detect the expression of autophagy-related proteins. Compared with that in the control group, the expression of p62 increased, whereas that of LC3 decreased, in the model and sh-NC groups. Furthermore, compared with levels in the model or sh-NC group, p62 was downregulated, whereas LC3 was upregulated, in the metformin, sh-TUG1, metformin + sh-TUG1, and atorvastatin groups ( Figure 6B and D) . Through qRT-PCR, we demonstrated that compared with that in the control group, the expression of TUG1 was increased in the model group and sh-NC group. Additionally, compared with those in the model or sh-NC group, the levels of TUG1 were decreased in the metformin, sh-TUG1, and metformin + sh-TUG1 groups ( Figure 6E ). Western blotting indicated that compared with that in the control group, the ratio of p-mTOR/mTOR was increased in the model or sh-NC group. Further, compared with that in the model or sh-NC group, the ratio of p-AMPK/ AMPK was increased, whereas that of p-mTOR/mTOR was decreased, in the metformin, sh-TUG1, metformin + sh-TUG1, and atorvastatin groups ( Figure 6F ).
Discussion
Atherosclerotic diseases such as CHD remain the leading cause of death worldwide; the lifetime risk of CHD is 67% in humans over 55 years of age. [27] [28] [29] Studies have shown that lncRNAs are vital regulatory factors in the progression of AS. [30] [31] [32] Thus, defining their functions might help to identify novel diagnostic and therapeutic targets for AS. In this study, we found that lncRNA TUG1 was significantly upregulated in the peripheral blood of patients with CHD compared with healthy individuals. This indicates that lncRNA TUG1 may promote CHD progression. Autophagy is the process through which cytoplasmic components such as proteins and organelles that need to be degraded are encapsulated and eventually transported to the lysosomes for degradation. Studies have shown that autophagy inhibits the progression of AS, whereas defective autophagy in vascular wall cells enhances its progression. 33, 34 In this study, we found that metformin and si-TUG1 reduced the proliferation and migration of HUVECs. There is a strong connection between autophagy and vascular wall cell proliferation/migration in AS. Research has suggested that autophagy defects in vascular smooth muscle cells might induce cell proliferation and migration, leading to the acceleration of AS progression. 35 However, the upregulation of autophagy in vascular wall cells is known to reduce proliferation and inhibit fibrosis. Markers involved in autophagy are classified as autophagy-related genes (ATGs), and approximately 30 ATGs are known to participate in different stages of autophagy, [37] [38] [39] including Beclin-1, ATG3, ATG5, ATG7, ATG8, and ATG12. 40 During autophagy, LC3I is converted to LC3II and p62 enters the autophagosome to be degraded; thus, the LC3II/I ratio and p62 are commonly used as indicators of autophagy. 41, 42 To explore the effect of TUG1 on autophagy, we measured the levels of autophagy-related proteins and several major signaling pathways. We found that the expression of p-mTOR/ mTOR and p62 was reduced when TUG1 was knocked down, whereas that of p-AMPK/AMPK and LC3II/LC3I was elevated, which was accompanied by an increase in ATG3 expression. C.C, which acts through the specific inhibition of p-AMPK in the AMPK/mTOR pathway, is recognized as an autophagy inhibitor. We found that the changes in protein expression induced by si-TUG1 could be reversed by C.C; at the same time, C.C successfully reversed the changes in proliferation and migration mediated by si-TUG1. These data suggest that si-TUG1 activates autophagy via the AMPK/mTOR pathway to suppress proliferation and migration. It has been reported that metformin can be used to treat diseases through the regulation of lncRNA expression. 43, 44 Because metformin was found to attenuate TUG1 expression in a time-dependent manner in the present study, we further investigated its correlation with TUG1 expression. The results indicated that metformin activates autophagy via lncRNA TUG1 in HUVECs. Finally, we established an AS rat model. As expected, immunohistochemistry and Western blotting in the metformin and sh-TUG1 groups were consistent with the results of our in vitro experiments. Interestingly, immunohistochemistry showed an increase in the expression of p62 and a decrease in that of LC3 in the AS model group compared with levels in the control group, indicating that autophagy was somewhat disrupted in rats of the AS model group. Furthermore, we found that atorvastatin treatment activated the AMPK/mTOR pathway; however, to the best of our knowledge, the role of atorvastatin in preventing AS via the AMPK/mTOR pathway has not yet been reported.
Conclusion
In summary, we provide clear evidence that metformin attenuates the progression of AS via lncRNA TUG1. This study not only expands our understanding of the role of metformin in preventing AS, but also provides new perspectives into its molecular mechanisms. TUG1 is also suggested to be potential a therapeutic target for the prevention of AS.
